EX-99.2 3 rkda-ex99_2.htm EX-99.2 EX-99.2

 

Exhibit 99.2

img193038000_0.jpg

 

Arcadia Biosciences, Inc.

Consolidated Balance Sheets

(Unaudited)

(In thousands, except share data)

 

 

 

 

 

 

 

 

 

 

March 31, 2025

 

 

December 31, 2024

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

3,159

 

 

$

4,242

 

Accounts receivable and other receivables, net of allowance for doubtful accounts of
   $0 as of March 31, 2025 and December 31, 2024

 

 

1,615

 

 

 

1,175

 

Inventories — current

 

 

1,285

 

 

 

904

 

Note receivable — current

 

 

1,964

 

 

 

1,894

 

Prepaid expenses and other current assets

 

 

727

 

 

 

931

 

Current assets of discontinued operations — GoodWheat

 

 

96

 

 

 

96

 

Total current assets

 

 

8,846

 

 

 

9,242

 

Property and equipment, net

 

 

28

 

 

 

41

 

Right of use asset

 

 

19

 

 

 

137

 

Intangible assets, net

 

 

39

 

 

 

39

 

Note receivable — noncurrent

 

 

3,966

 

 

 

3,966

 

Other noncurrent assets

 

 

92

 

 

 

92

 

Total assets

 

$

12,990

 

 

$

13,517

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable and accrued expenses

 

$

1,895

 

 

$

2,108

 

Amounts due to related parties

 

 

30

 

 

 

30

 

Operating lease liability — current

 

 

21

 

 

 

155

 

Other current liabilities

 

 

270

 

 

 

270

 

Total current liabilities

 

 

2,216

 

 

 

2,563

 

Common stock warrant and option liabilities

 

 

869

 

 

 

2,731

 

Other noncurrent liabilities

 

 

1,000

 

 

 

2,000

 

Total liabilities

 

 

4,085

 

 

 

7,294

 

Commitments and contingencies (Note 14)

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

Common stock, $0.001 par value—150,000,000 shares authorized as
   of March 31, 2025 and December 31, 2024; 1,367,040 and 1,364,940 shares issued
   and outstanding as of March 31, 2025 and December 31, 2024, respectively

 

 

65

 

 

 

65

 

Additional paid-in capital

 

 

285,119

 

 

 

285,036

 

Accumulated deficit

 

 

(276,279

)

 

 

(278,878

)

Total stockholders' equity

 

 

8,905

 

 

 

6,223

 

Total liabilities and stockholders’ equity

 

$

12,990

 

 

$

13,517

 

 

1


 

 

 

Arcadia Biosciences, Inc.

Consolidated Statements of Operations and Comprehensive Income (Loss)

(Unaudited)

(In thousands, except share data and per share data)

 

 

 

Three Months Ended March 31,

 

 

 

 

2025

 

 

 

2024

 

Revenues:

 

 

 

 

 

 

Product

 

$

1,200

 

 

$

987

 

Total revenues

 

 

1,200

 

 

 

987

 

Operating expenses (income):

 

 

 

 

 

 

Cost of revenues

 

 

682

 

 

 

471

 

Research and development

 

 

 

 

 

6

 

Gain on sale of intangible assets

 

 

(750

)

 

 

 

Impairment of property and equipment

 

 

 

 

 

36

 

Change in fair value of contingent consideration

 

 

(1,000

)

 

 

 

Selling, general and administrative

 

 

1,738

 

 

 

2,062

 

Total operating expenses

 

 

670

 

 

 

2,575

 

Income (loss) from continuing operations

 

 

530

 

 

 

(1,588

)

Interest income

 

 

207

 

 

 

45

 

Other income, net

 

 

 

 

 

3

 

Change in fair value of common stock warrant and option liabilities

 

 

1,862

 

 

 

593

 

Net income (loss) from continuing operations

 

 

2,599

 

 

 

(947

)

Net loss from discontinued operations

 

 

 

 

 

(1,476

)

Net income (loss) attributable to common stockholders

 

$

2,599

 

 

$

(2,423

)

Net income (loss) per share attributable to common stockholders:

 

 

 

 

 

 

Basic from continuing operations

 

$

1.90

 

 

$

(0.70

)

Basic from discontinued operations

 

$

 

 

$

(1.08

)

Net income (loss) per basic share attributable to common stockholders

 

$

1.90

 

 

$

(1.78

)

Diluted from continuing operations

 

$

1.90

 

 

$

(0.70

)

Diluted from discontinued operations

 

$

 

 

$

(1.08

)

Net income (loss) per diluted share attributable to common stockholders

 

$

1.90

 

 

$

(1.78

)

Weighted-average number of shares used in per share
   calculations:

 

 

 

 

 

 

Basic

 

 

1,366,060

 

 

 

1,361,657

 

Diluted

 

 

1,366,203

 

 

 

1,361,657

 

Other comprehensive income (loss), net of tax

 

 

 

 

 

 

Unrealized gains on available-for-sale securities

 

$

 

 

$

60

 

Other comprehensive income

 

$

 

 

$

60

 

Comprehensive income (loss) attributable to common stockholders

 

$

2,599

 

 

$

(2,363

)

 

2


 

Arcadia Biosciences, Inc.

Consolidated Statements of Cash Flows

(Unaudited)

(In thousands)

 

 

Three Months Ended March 31,

 

 

 

 

2025

 

 

 

2024

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

Net income (loss)

 

$

2,599

 

 

$

(2,423

)

Adjustments to reconcile net income to cash used in operating activities:

 

 

 

 

 

 

Change in fair value of common stock warrant and option liabilities

 

 

(1,862

)

 

 

(593

)

Change in fair value of contingent consideration

 

 

(1,000

)

 

 

 

Depreciation

 

 

13

 

 

 

51

 

Lease amortization

 

 

104

 

 

 

177

 

Amortization of note receivable

 

 

(69

)

 

 

 

Loss on sale of property and equipment

 

 

 

 

 

2

 

Gain on sale of intangible assets

 

 

(750

)

 

 

 

Stock-based compensation

 

 

78

 

 

 

138

 

Impairment of property and equipment

 

 

 

 

 

36

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

Accounts receivable and other receivables

 

 

(193

)

 

 

(246

)

Inventories

 

 

(381

)

 

 

303

 

Prepaid expenses and other current assets

 

 

205

 

 

 

275

 

Accounts payable and accrued expenses

 

 

(213

)

 

 

(678

)

Amounts due to related parties

 

 

 

 

 

17

 

Operating lease liabilities

 

 

(119

)

 

 

(269

)

Net cash used in operating activities

 

 

(1,588

)

 

 

(3,210

)

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

Proceeds from sale of intangible assets

 

 

500

 

 

 

 

Proceeds from sale of property and equipment

 

 

 

 

 

17

 

Purchases of property and equipment

 

 

 

 

 

(13

)

Net cash provided by investing activities

 

 

500

 

 

 

4

 

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

Proceeds from ESPP purchases

 

 

5

 

 

 

5

 

Net cash provided by financing activities

 

 

5

 

 

 

5

 

Net decrease in cash and cash equivalents

 

 

(1,083

)

 

 

(3,201

)

Cash and cash equivalents — beginning of period

 

 

4,242

 

 

 

6,518

 

Cash and cash equivalents — end of period

 

$

3,159

 

 

$

3,317

 

NONCASH INVESTING AND FINANCING ACTIVITIES:

 

 

 

 

 

 

Proceeds from sale of property and equipment in accounts receivable and other receivables

 

$

 

 

$

12

 

Purchases of property and equipment in accounts payable and accrued expenses

 

$

 

 

$

13

 

Right of use assets obtained in exchange for new operating lease liabilities

 

$

 

 

$

86

 

Proceeds from sale of intangible assets in accounts receivable and other receivables

 

$

250

 

 

$

 

 

 

# # #

3